This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Plasma Phospho-tau217 in Alzheimer Disease (AD)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Plasma Phospho-tau217in Alzheimer Disease (AD)

Alzheimer disease (AD) pathology starts with a prolonged phase of beta-amyloid (Abeta) accumulation without symptoms

  • importance of this presymptomatic, or preclinical, stage has been reported by studies finding that Abeta measured by cerebrospinal fluid (CSF) biomarkers or positron emission tomography (PET) predicted cognitive decline in people who were cognitively unimpaired (CU)

  • plasma P-tau217 predicted cognitive decline in patients with preclinical AD (1)
    • findings suggest that plasma P-tau217 may be used as a complement to CSF or PET for participant selection in clinical trials of novel disease-modifying treatments

  • been shown that plasma P-tau217 differentiated clinically diagnosed AD dementia from other neurodegenerative disorders (2)
    • also distinguished participants with neuropathologically defined AD from participants without diagnostic levels of AD histopathology
    • plasma P-tau217 levels correlated with cerebral tau tangles and discriminated abnormal vs normal tau-PET scans with significantly higher accuracy than plasma P-tau181, plasma NfL, CSF P-tau181, CSF Abeta42:Abeta40 ratio, and MRI measures

Reference:

  • Mattsson-Carlgren N et al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurol. Published online February 06, 2023. doi:10.1001/jamaneurol.2022.5272
  • Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, Su Y, Chen Y, Serrano GE, Leuzy A, Mattsson-Carlgren N, Strandberg O, Smith R, Villegas A, Sepulveda-Falla D, Chai X, Proctor NK, Beach TG, Blennow K, Dage JL, Reiman EM, Hansson O. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020 Aug 25;324(8):772-781. doi: 10.1001/jama.2020.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.